Download PDF
Dtsch Med Wochenschr 2013; 138(37): 1852-1855
DOI: 10.1055/s-0033-1343346
Kommentar | Commentary
Rheumatologie
© Georg Thieme Verlag KG Stuttgart · New York

Zelltherapie in der Rheumatologie: Chancen und Risiken der Therapie mit mesenchymalen Stromazellen

Mesenchymal stroma cells (MSCs) for the treatment of rheumatic disease
M. Schmitt
1   Universitätsklinikum Heidelberg, Medizinische Klinik V (Hämatologie, Onkologie, Rheumatologie), Universität Heidelberg, Heidelberg
,
L.P. Müller
2   Universitätsklinikum Halle (Saale), Universitätsklinik und Poliklinik für Innere Medizin IV
,
G. Keyßer
3   Universitätsklinikum Halle (Saale), Universitätsklinik und Poliklinik für Innere Medizin II, Arbeitsbereich Rheumatologie
,
H.-M. Lorenz
1   Universitätsklinikum Heidelberg, Medizinische Klinik V (Hämatologie, Onkologie, Rheumatologie), Universität Heidelberg, Heidelberg
,
A. D. Ho
1   Universitätsklinikum Heidelberg, Medizinische Klinik V (Hämatologie, Onkologie, Rheumatologie), Universität Heidelberg, Heidelberg
,
P. Wuchter
1   Universitätsklinikum Heidelberg, Medizinische Klinik V (Hämatologie, Onkologie, Rheumatologie), Universität Heidelberg, Heidelberg
› Author Affiliations
Further Information

Publication History

17 May 2013

12 June 2013

Publication Date:
04 September 2013 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

mesenchymale Stromazellen (MSC) - Immunmodulation - Systemische Sklerose - Rheumatoide Arthritis

Keywords

mesenchymal stromal cells - immune modulation - systemic sclerosis - rheumatoid arthritis
 

  • Literatur

  • 1 Aurich I, Mueller LP, Aurich H et al. Functional integration of hepatocytes derived from human mesenchymal stem cells into mouse livers. Gut 2007; 56: 405
    CrossrefPubMedSearch in Google Scholar
  • 2 Bieback K, Wuchter P, Besser D et al. Mesenchymal stromal cells (MSCs): science and friction. J Mol Med 2012; 90: 773-782
    CrossrefPubMedSearch in Google Scholar
  • 3 Bocelli-Tyndall C, Zajac P, Di Maggio N et al. Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells. Arthritis Rheum 2010; 62: 3815-3825
    CrossrefPubMedSearch in Google Scholar
  • 4 Bouffi C, Bony C, Courties G et al. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS ONE 2010; 5: e14247
    CrossrefPubMedSearch in Google Scholar
  • 5 Carrion F, Nova E, Ruiz C et al. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus 2010; 19: 317-322
    CrossrefPubMedSearch in Google Scholar
  • 6 Crisan M, Yap S, Casteilla L et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3: 301-313
    CrossrefPubMedSearch in Google Scholar
  • 7 Dazzi F, van Laar JM, Cope A et al. Cell therapy for autoimmune diseases. Arth Res Ther 2007; 9: 206
    CrossrefPubMedSearch in Google Scholar
  • 8 Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317
    CrossrefPubMedSearch in Google Scholar
  • 9 Greenbaum A, Hsu YS, Day RB et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 2013; 495: 227-230
    CrossrefPubMedSearch in Google Scholar
  • 10 Gu Z, Akiyama K, Ma X et al. Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice. Lupus 2010; 19: 1502-1514
    CrossrefPubMedSearch in Google Scholar
  • 11 Guiducci S, Manetti M, Romano E et al. Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro. Ann Rheum Dis  2011; 70: 2011-2021
    CrossrefPubMedSearch in Google Scholar
  • 12 Ho AD, Wagner W, Franke W. Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy 2008; 10: 320-330
    CrossrefPubMedSearch in Google Scholar
  • 13 Keyßer G, Christopeit M, Fick S et al. Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases. Arthritis Rheum 2011; 63: 2540-2542
    CrossrefPubMedSearch in Google Scholar
  • 14 Le Blanc K, Mougiakakos D. Multipotent meenchymal stromal cells and the innate immune system. Nature Reviews 2012; 12: 383-396
    CrossrefPubMedSearch in Google Scholar
  • 15 Liang J, Zhang H, Hua B et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 2010; 69: 1423-1429
    CrossrefPubMedSearch in Google Scholar
  • 16 Luria EA, Panasyuk AF, Friedenstein AY. Fibroblast colony formation from monolayer cultures of blood cells. Transfusion 1971; 11: 345-349
    CrossrefPubMedSearch in Google Scholar
  • 17 MacDonald GIA, Augello A, De Bari C. Role of mesenchymal stem cells in reestablishing immunologic tolerance in autoimmune rheumatic diseases. Arthritis Rheum 2011; 63: 2547-2557
    CrossrefPubMedSearch in Google Scholar
  • 18 Mendez-Ferrer S, Michurina TV, Ferraro F et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010; 466: 829-834
    CrossrefPubMedSearch in Google Scholar
  • 19 Mougiakakos D, Jitschin R, Johansson CC et al. The impact of inflammatory licensing on heme oxygenase- 1- mediated induction of regulatory T cells by human Mesenchymal stem cells. Blood 2011; 117: 4826-4835
    CrossrefPubMedSearch in Google Scholar
  • 20 Mueller LP, Luetzkendorf J, Mueller T et al. Presence of Mesenchymal Stem Cells in Human Bone Marrow After Exposure to Chemotherapy: Evidence of Resistance to Apoptosis Induction. Stem Cells 2006; 24:  2753-2765
    CrossrefPubMedSearch in Google Scholar
  • 21 Murphy JM, Dixon K, Beck S et al. Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum 2002; 46:  704-713
    CrossrefPubMedSearch in Google Scholar
  • 22 Németh K, Leelahavanichkul A, Yuen PST et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production. Nature Medicine 2009; 15: 42-49
    CrossrefPubMedSearch in Google Scholar
  • 23 Petrie Aronin CE, Tuan RS. Therapeutic potential of the immunomodulatory activities of adult mesenchymal stem cells. Birth Defects Res C Embryo Today 2010; 90: 67-74
    CrossrefPubMedSearch in Google Scholar
  • 24 Prigione I, Benvenuto F, Bocca P et al. Reciprocal interactions between human mesenchymal stem cells and γδ T cells or invariant natural killer T cells. Stem Cells 2009; 27: 693-702
    CrossrefPubMedSearch in Google Scholar
  • 25 Sugiyama T, Kohara H, Noda M et al. Maintenance of the hematopoietic stem cell pool by CXCL12–CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006; 25: 977-988
    CrossrefPubMedSearch in Google Scholar
  • 26 Sun L, Akiyama K, Zhang H et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009; 27: 1421-1432
    CrossrefPubMedSearch in Google Scholar
  • 27 Sun L, Wang D, Liang J et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 2010; 62: 2467-2475
    CrossrefPubMedSearch in Google Scholar
  • 28 Tyndall A, Furst ED. Adult stem cell treatment of scleroderma. Curr Opin Rheumatol 2007; 19: 604-610
    CrossrefPubMedSearch in Google Scholar
  • 29 Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Rev Immunol 2008; 8: 726-736
    CrossrefPubMedSearch in Google Scholar
  • 30 von Bahr L, Batsis I, Moll G et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 2012; 30:  1575-1578
    CrossrefPubMedSearch in Google Scholar
  • 31 Wagner W, Feldmann Jr RE, Seckinger A et al. The heterogeneity of human mesenchymal stem cell preparations--evidence from simultaneous analysis of proteomes and transcriptom. Exp Hematol 2006; 34: 536-548
    CrossrefPubMedSearch in Google Scholar
  • 32 Wagner W, Roderburg C, Wein F et al. Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors. Stem Cells 2007; 25: 2638-2647
    CrossrefPubMedSearch in Google Scholar
  • 33 Wuchter P, Boda-Heggemann J, Straub BK et al. Processus and recessus adhaerentes: giant adherens cell junction systems connect and attract human mesenchymal stem cells. Cell Tissue Res 2007; 328: 499-514
    CrossrefPubMedSearch in Google Scholar
  • 34 Xu J, Wang D, Liu D et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood 2012; 120: 3142-3151
    Search in Google Scholar
  • 35 Zhou K, Zhang H, Jin O et al. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol 2008; 5: 417-424
    CrossrefPubMedSearch in Google Scholar